Riskpilot← Back to searchSign inGet full accessFENIX Scientific AB
ABActiveOrg 5568709678Tibastvägen 33Business and other management consultancy activities · NACE 7020Est. 20111 employees
Revenue 2025
SEK 867K
+832% vs 2024
EBITDA margin
39.3%
+2523% vs 2024
Equity ratio
65.4%
Financial strength
Net profit 2025
SEK 714K
+2756% vs 2024
| Revenue | SEK 867K | +832% |
| EBITDA | SEK 341K | +2523% |
| Net profit | SEK 714K | +2756% |
| Total assets | SEK 1,4M | +216% |
| Equity | SEK 887K | +318% |
| Employees | 1 | — |
Legal name
FENIX Scientific AB
Org number
5568709678
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
7 november 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning, konsultverksamhet och kommunikation inom livsvetenskaper, miljö och medicin/hälsa samt stödja privatpersoner, företag, branschorganisationer och andra aktörer att planera, söka, förhandla och administrera anslag från olika anslagsgivare samt bedriva därmed förenlig verksamhet.
Address
Tibastvägen 33
Phone
+46706047615
Email
ingemar.pongratz@pongratzconsulting.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 170 | 323 | 349 | 93 | 867 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −164 | 132 | 24 | 13 | 341 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −164 | 132 | 24 | 13 | 341 |
| Net financials | 84 | 1 | 3 | 21 | 520 |
| Profit before tax | −79 | 133 | 27 | 34 | 770 |
| Tax | −0 | −0 | −3 | −9 | −56 |
| Net profit | −79 | 133 | 24 | 25 | 714 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 117 | 204 | 365 | 429 | 1 357 |
| Equity | 30 | 163 | 187 | 212 | 887 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 87 | 41 | 178 | 217 | 379 |
| Total debt | 87 | 41 | 178 | 217 | 379 |
EBITDA margin
39.3%
This company
15.8%
Market median
+149% vs market
20212025
Equity ratio
65.4%
This company
38.2%
Market median
+71% vs market
20212025
Return on equity
80.5%
This company
18.4%
Market median
+338% vs market
20212025
Net profit margin
82.4%
This company
8.1%
Market median
+917% vs market
20212025
Asset turnover
0.64×
This company
1.12×
Market median
-43% vs market
20212025
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KG Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FENIX Scientific AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Göran Johansson | Audit | 0 companies |
| Ingemar Göran Pongratz | Board of Directors | 0 companies |
| Alba Leonila Aviles De Pongratz | Deputy Board Member | 0 companies |